"Using translational modelling to evaluate preclinical tumour models"

 
Tumour Models London, 4 Dec 2018
Workshop

16. Using translational modelling to evaluate preclinical tumour models. Tumour models (Hanson Wade), DoubleTree by Hilton Hotel London - Docklands Riverside, London (12/2018) PDF (Part 1), PDF (Part 2)

 

Objectives

• How do we define the quantitative relationship between preclinical efficacy and clinical activity for the same treatment? 

• Is it possible to set minimum preclinical efficacy criteria to qualify a novel treatment for clinical success? 

• How to apply translational modelling framework to best support drug projects? Where does it add value? 

• Which ideas can be borrowed to support immuno-oncology projects?

Introductions

• Cancer drug discovery & development pain points

 

Discussion 1

How do you select the optimal combination treatment for clinical trials?

 

Lecture 1. Translational modelling for cell-directed cancer therapies: the successful case studies

The lecture will provide a historical perspective for translational modelling that has been developed for chemotherapies and cancer cell-directed targeted therapies. It will discuss the following topics:

• How do we define the quantitative relationship between preclinical efficacy and clinical activity for this type of treatment?

• What does compelling preclinical evidence entail?

• Is it possible to set minimum preclinical efficacy criteria to qualify a novel treatment for clinical success?

Case study: Evaluate PC-9 xenograft as an efficacy model for EGFR using afatinib preclinical and clinical data

Case study: Evaluate Mia PaCa2 xenograft as an efficacy model for gemcitabine using preclinical and clinical data

Discussion 2

• Limitations of the approach/conclusions

• How to apply translational modelling framework to best support drug projects?

• Where does it add value?

• Which ideas can be borrowed to support immuno-oncology projects?

 

Lecture 2. Insights into patient-derived xenograft models

This lecture will focus on the Novartis Mouse Clinical Trial data to tackle 3 important questions, including:

• Which tumour growth rate laws can accurately recapitulate control PDX growth?

• Which tumour growth rate laws can accurately predict control PDX growth?

• Can we build a gene signature to predict control PDX growth?

Case study: Compare tumour growth rate laws with Novartis mouse clinical trial data

 

Discussion 3

• Evaluate the strategies put forward in Discussion 1

• What is the one action I will take after the workshop and why?

Company registration no. 09698685

Registered in England and Wales.

14 Tytherington Park Road, Macclesfield, Cheshire, UK  SK10 2EL 

Beyond Consulting Ltd

+44-7853 073 731